Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52.9M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
16.9K
-
Shares change
-
0
-
Total reported value, excl. options
-
$52.3K
-
Price
-
$3.10
Significant Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q4 2023
1 filings reported holding PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share as of Q4 2023.
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.9K shares
of 52.9M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.48M shares), JPMORGAN CHASE & CO (3.93M shares), BlackRock Inc. (3.23M shares), ArrowMark Colorado Holdings LLC (2.71M shares), Euclidean Capital LLC (2.63M shares), VANGUARD GROUP INC (2.41M shares), ALKEON CAPITAL MANAGEMENT LLC (2.35M shares), Woodline Partners LP (1.79M shares), Verition Fund Management LLC (1.58M shares), and PFM Health Sciences, LP (1.47M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.